Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytodyn Inc (CYDY)

Cytodyn Inc (CYDY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 408,491
  • Shares Outstanding, K 1,265,854
  • Annual Sales, $ 0 K
  • Annual Income, $ 3,750 K
  • EBIT $ -18 M
  • EBITDA $ -17 M
  • 60-Month Beta 1.33
  • Price/Sales N/A
  • Price/Cash Flow 98.20
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.01
  • Most Recent Earnings $0.00 on 10/10/25
  • Next Earnings Date 01/13/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2406 +34.12%
on 11/13/25
0.3799 -15.06%
on 11/24/25
+0.0812 (+33.62%)
since 11/12/25
3-Month
0.2260 +42.79%
on 10/31/25
0.3799 -15.06%
on 11/24/25
+0.0369 (+12.91%)
since 09/12/25
52-Week
0.1051 +207.04%
on 12/31/24
0.4945 -34.74%
on 02/24/25
+0.1947 (+152.11%)
since 12/12/24

Most Recent Stories

More News
CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium

Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells Remarkably longer survival was observed in patients treated with...

CYDY : 0.3227 (-1.38%)
CytoDyn Announces Resolution of Class Action Lawsuit

VANCOUVER, Washington, Dec. 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized...

CYDY : 0.3227 (-1.38%)
CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium

Company to deliver a poster presentation on clinical data demonstrating sustained remission following immune checkpoint inhibitor therapy with or after leronlimab treatment in patients with metastatic...

CYDY : 0.3227 (-1.38%)
CytoDyn Secures $30 Million Commitment from Yorkville Advisors

VANCOUVER, Washington, Nov. 03, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized...

CYDY : 0.3227 (-1.38%)
Halper Sadeh LLC Encourages CytoDyn Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

CYDY : 0.3227 (-1.38%)
CytoDyn to Present at the LD Micro Main Event XIX Investor Conference

CFO Robert E. Hoffman to deliver company presentation on October 21, 2025 VANCOUVER, Washington, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY)  ("CytoDyn" or the "Company"), a clinical-stage...

CYDY : 0.3227 (-1.38%)
September 2025 Letter to Shareholders

VANCOUVER, Washington, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As this pivotal year continues to take shape for CytoDyn Inc. (“CytoDyn” or the “Company”), I am pleased to...

CYDY : 0.3227 (-1.38%)
CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity

Company to deliver oral and poster presentations for data on leronlimab’s action on PD-L1 expression and patient survival in triple-negative breast cancer VANCOUVER, Washington, Sept. 25, 2025 ...

CYDY : 0.3227 (-1.38%)
CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity

VANCOUVER, Washington, Sept. 16, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY)  ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized...

CYDY : 0.3227 (-1.38%)
CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

VANCOUVER, Washington, Sept. 04, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY)  ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized...

CYDY : 0.3227 (-1.38%)

Business Summary

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has...

See More

Key Turning Points

3rd Resistance Point 0.3361
2nd Resistance Point 0.3328
1st Resistance Point 0.3277
Last Price 0.3227
1st Support Level 0.3193
2nd Support Level 0.3160
3rd Support Level 0.3109

See More

52-Week High 0.4945
Fibonacci 61.8% 0.3457
Last Price 0.3227
Fibonacci 50% 0.2998
Fibonacci 38.2% 0.2539
52-Week Low 0.1051

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar